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Aims: Diabetes mellitus is associated with metabolic bone disease and increased low-
impact fractures. The insulin-sensitizer metformin possesses in vitro, in vivo and ex vivo
osteogenic effects, although this has not been adequately studied in the context of diabetes.
We evaluated the effect of insulin-deficient diabetes and/or metformin on bone micro-
architecture, on osteogenic potential of bone marrow progenitor cells (BMPC) and possible
mechanisms involved.
Methods: Partially insulin-deficient diabetes was induced in rats by nicotinamide/strepto-
zotocin-injection, with or without oral metformin treatment. Femoral metaphysis micro-
architecture, ex vivo osteogenic potential of BMPC, and BMPC expression of Runx-2, PPARg
and receptor for advanced glycation endproducts (RAGE) were investigated.
Results: Histomorphometric analysis of diabetic femoral metaphysis demonstrated a slight
decrease in trabecular area and a significant reduction in osteocyte density, growth plate
height and TRAP (tartrate-resistant acid phosphatase) activity in the primary spongiosa.
BMPC obtained from diabetic animals showed a reduction in Runx-2/PPARg ratio and in their
osteogenic potential, and an increase in RAGE expression. Metformin treatment prevented
the diabetes-induced alterations in bone micro-architecture and BMPC osteogenic potential.
Conclusion: Partially insulin-deficient diabetes induces deleterious effects on long-bone
micro-architecture that are associated with a decrease in BMPC osteogenic potential, which
could be mediated by a decrease in their Runx-2/PPARg ratio and up-regulation of RAGE.
These diabetes-induced alterations can be totally or partially prevented by oral adminis-
tration of metformin.
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In recent years there has been a growing interest in the
association between diabetes and alterations in bone metab-
olism, which has given rise to substantial research on the
effects of diabetes and of anti-diabetic drug intake on bone
health [1]. Type 1 diabetes has been clearly associated with
low bone mass and a 6-fold increase in low-impact fractures.
On the other hand, the effects of type 2 diabetes on bone are
less clear-cut: whereas bone mineral density has been
reported to be either unchanged or modestly increased,
incidence of low-stress fractures is almost doubled, pointing
to a decrease in the bone quality of these patients [2–4].
Additionally, in both types of diabetes there is delayed
fracture healing [5]. Diabetes-associated alterations in bone
quality and repair have been related to poor glycemic control,
to an increase in reactive oxygen species (ROS) production,
and to bone matrix accumulation of advanced glycation
endproducts (AGEs) [6–8]. In spite of all these reports, the
underlying mechanisms of diabetes-induced bone altera-
tions are incompletely known.
AGEs accumulation in the extracellular matrix alters bone
mechanical properties through the excessive formation of
nonenzymatic crosslinks between collagen chains, thus
generating irreversible intra- and inter-molecular covalent
bonds [9]. Additionally, collagen AGEs accumulation also
induces alterations in bone cell homeostasis, mainly due to
the specific recognition of AGEs by receptors such as RAGE that
in osteoblasts activate intracellular signaling pathways
leading to a decrease in free IGF-1 levels, and to a reduction
in osteoblastic proliferation, differentiation, mineralization
and survival [10–15]. Interestingly, AGEs recognition by RAGE
up-regulates the expression of this receptor, thus providing a
positive feedback loop that can increase the osteoblastic
response to extracellular AGEs accumulation [16–18].
Osteoblasts and adipocytes derive through divergent and
mutually inhibitory processes, from a common pluripotent
precursor: the bone marrow progenitor cell (BMPC) of
mesenchymal origin. BMPC osteoblastic differentiation is
induced by the transcription factor Runx2 [19], while adipo-
cytic differentiation is controlled by peroxisome proliferator-
activated receptor-g (PPARg) [20]. Rodent models of type 1
diabetes show an increase in bone marrow adiposity and
PPARg activity, and a decrease in osteoblastic density with low
bone mass, suggesting that their bone phenotype could be the
consequence of an increase in the expression of PPARg by
BMPC [21]. In type 2 diabetes, BMPC phenotypic commitment
to the osteoblastic/adipocytic lineage has not been established
to date.
The possible effects on bone metabolism of insulin-
sensitizing agents have also been studied. Thiazolidinediones
induce BMPC adipogenesis and thus bone marrow adiposity,
by binding to PPARg2 receptors and enhancing expression of
the adipogenic transcription factor aP2 [20,22]. Treatment of
mice with thiazolidinediones decreases bone mineral content,
bone formation, and trabecular bone volume, by decreasing
Runx2 expression [22,23]. On the other hand, we have
previously demonstrated that the biguanide metformin,
widely used for treatment of type 2 diabetes, has osteogeniceffects. In vitro, metformin can directly stimulate the
proliferation, differentiation and mineralization of osteoblasts
[24]. Metformin can also prevent the deleterious effects of
AGEs on osteoblasts in culture, in part by blocking the AGEs-
induced up-regulation of RAGE [17]. Oral administration of
metformin to non-diabetic animals stimulates the osteogenic
potential of BMPC and improves bone healing, by increasing
the expression of Runx2 [25]. Due to its antioxidant and
insulin-sparing effects, as well as its ability to improve
cardiovascular outcomes, metformin is presently under
evaluation as an adjunct therapy in patients with type 1
diabetes mellitus [26].
Based on these considerations, we hypothesized that
diabetes-induced deleterious effects on bone metabolism,
particularly alterations in long bone micro-architecture,
could be partly due to a decrease in the osteogenic potential
of BMPC; and that these alterations could be prevented by
metformin treatment. To prove our hypothesis, we evaluated
the effect of partially insulin-deficient diabetes and/or oral
metformin administration in rats, on femoral metaphysis
micro-architecture and BMPC osteogenic potential. We also
studied possible mechanisms of action, such as expression of
RAGE, Runx-2/PPARg ratio, and pro-inflammatory cytokine
levels.
2. Materials and methods
2.1.1. Animal treatments
Two-month-old male Sprague-Dawley rats (190–210 g) were
used. Animals were maintained in a temperature-controlled
room at 23 8C, with a fixed 12 h light: 12 h darkness cycle, and
fed standard rat laboratory chow and water ad libitum. All
experiments on animals were done in conformity with the
Guidelines on Handling and Training of Laboratory Animals
published by the Universities Federation for Animals Welfare
[27]. Approval for animal studies was obtained from the
institutional accreditation committee (INIBIOLP’s Animal
Welfare Assurance No A5647-01). In half the animals, partially
insulin-deficient diabetes mellitus was induced by i.p. injec-
tion of nicotinamide (NA) (50 mg/kg) in physiological saline
followed by i.p. streptozotocin (STZ) (60 mg/kg) freshly
dissolved in citrate buffer (0.05 M, pH 4.5) [28]. One week
later, blood glucose was assayed to verify diabetes in all NA-
STZ-treated animals. Animals were then divided into four
groups of 10 animals per group: control (non-treated non-
diabetic) (C) and diabetic rats (D) received water ad libitum;
metformin-treated non-diabetic (M) and diabetic rats (D-M)
received 100 mg/kg/day of metformin (Quı́mica Montpellier,
Buenos Aires, Argentina) in drinking water for 2 weeks. After
all treatments non-fasting blood samples were taken, and
serum was stored at 20 8C until biochemical evaluation.
Serum glucose and triglycerides were measured by commer-
cial kits (Wiener Laboratories, Argentina), insulin by a rat-
specific ELISA kit from ALPCO and fructosamine by a
colorimetric BioSystems kit. Serum pro-inflammatory status
was assessed by evaluation of plasmatic TNFa by an ELISA kit
(BD OptEIATM mouse TNF (Mono/Mono) as we have previously
described [29].
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After all treatments rats were sacrificed under anesthesia by
neck dislocation, and femora were processed for histological
and quantitative histomorphometric analysis. Bones were
fixed in 10% formalin and decalcified in 10% EDTA, embedded
in paraffin and 5 mm sections were obtained with an SM 2000R
Leica microtome. The sections were stained with hematoxy-
lin–eosin (H–E); tartrate-resistant acid phosphatase histo-
chemistry (TRAP) (Sigma, Buenos Aires Argentina) to
specifically identify osteoclasts; or Alcian Blue (AB) to evaluate
the growth cartilage [25]. Pictures were taken with a Nikon
Coolpix 4500 digital camera on an Eclipse E400 Nikon
microscope. Images were analyzed using the Image J program
(www.macbiophotonics.ca/imagej) with a Microscope scale
plugin. In all experimental groups, microarchitecture of
femoral metaphysis (trabecular volume and osteocytic densi-
ty) was evaluated by H-E, and the average heights of femoral
growth plates was determined by AB. Osteoclastic density in
the primary spongiosa was calculated as the positive TRAP
area per square millimeter (Oc/mm2) [25].
2.3. Bone marrow progenitor cell (BMPC) isolation and
incubations
BMPC were obtained from all experimental groups as previously
described [25]. Briefly, bone marrow cells were collected by
flushing femora and tibiae of the animals with Dulbecco’s
modified essential medium (DMEM) (Invitrogen, Buenos Aires,
Argentina) under sterile conditions. The obtained suspension
was seeded in a 25 cm2 tissue culture flask and incubated in
DMEM supplemented with penicillin (100 UI/ml), streptomycin
(100 mg/ml) and 10% fetal bovine serum (FBS) (Natocor, Córdoba,
Argentina) at 37 8C in a humidified atmosphere with 5% CO2 and
95% air. Non-adherent cells were removed by changing the
medium after 24 h. The culture medium was changed twice a
week. When cells reached confluence, the cell monolayer was
detached using 0.12% trypsin–1 mM EDTA and sub-cultured in
tissue culture plates.
2.4. Osteogenic differentiation of BMPC
BMPC were plated at a density of 5  104 cells/well in 24-well
plates with 10% FBS-DMEM and incubated at 37 8C. After cells
reached confluence, they were induced to differentiate into
osteoblasts using an osteogenic medium (DMEM-10% FBS
containing 25 mg/ml ascorbic acid and 5 mM sodium b-
glycerol-phosphate) for a further 15 or 21 days [25]. Medium
was changed twice a week. To evaluate alkaline phosphatase
(ALP) activity, cell monolayers were washed with phosphate
buffered saline (PBS) and lysed with 0.1% Triton-X100. An
aliquot was used to determine ALP activity by hydrolysis of p-
nitrophenylphosphate (p-NPP) into p-nitrophenol (p-NP) at
37 8C for 1 h, recording the absorbance at 405 nm. Other
aliquots were used for protein determination by Bradford’s
technique [30]. Type I collagen production was measured as
previously reported [25]. Briefly, cell monolayers were fixed
with Bouin’s solution and stained with Sirius red dye for 1 h.
The stained material was dissolved in 1 ml of 0.1 N sodium
hydroxide and the absorbance of the solution was recorded at550 nm. Extracellular calcium deposits (mineralization
nodules) were also evaluated using Alizarin S red staining
[25]. Stained calcium deposits were extracted with 1 ml of
0.1 N sodium hydroxide, recording absorbance at 548 nm.
Alternatively, stained cultures were observed using a Nikon
microscope and photographed.
2.5. Western blot analysis
BMPC were grown to confluence in 6-well plates in DMEM-10%
FBS and differentiated for 15 days to osteoblasts as described
above. At the end of the culture periods, cells were lysed in
Laemmli’s buffer [31], heated to 100 8C for 3 min, and subjected
to 12% SDS-PAGE. The separated proteins were then trans-
ferred to PVDF membranes. After washing and blocking, the
membranes were incubated overnight at 4 8C with an antibody
directed against the osteoblastogenic transcription factor
Runx-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or
the adipogenic factor PPARg (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). In order to normalize results, all blots were
stripped and re-probed with an anti b-actin antibody (Sigma,
St. Louis, MO, USA) [25]. In addition, RAGE expression was
assessed with an anti-RAGE antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) [17]. Blots were developed by an
enhanced chemiluminescence method. The intensity of the
specific bands was quantified by densitometry after scanning
of the photographic film. Images were analyzed using the
Scion-beta 2 program.
2.6. Statistical analysis
Results are expressed as the mean  SEM and were obtained
from three separate experiments. Differences between the
groups were assessed by one-way ANOVA using the Tukey
post hoc test. For non - normal distributed data, the non -
parametrical Kruskal–Wallis test with Dunn post hoc test was
performed, using GraphPad In Stat, version 3.00 (Graph Pad
Software, San Diego, CA, USA). P < 0.05 was considered
significant for all statistical analyses.
3. Results
3.1.1. Biochemical evaluation of partially insulin-deficient
diabetic rats
For these studies we have used a model of partially insulin-
deficient diabetes [28] that is induced in rats by consecutive i.p.
injection of nicotinamide and streptozotocin. After one week,
diabetic and non-diabetic animals were either not treated
(groups C and D) or treated with metformin (groups M and D-
M) for an additional 2 weeks. Table 1 shows the non-fasting
serum biochemical profile and levels of pro-inflammatory
cytokines of all groups. Significantly elevated levels of serum
glucose (about 3-fold of C animals), triglycerides (4-fold of C),
fructosamine (1.6-fold of C) and TNFa (5-fold of C) were
detected in D animals, while insulin was decreased (36% of C).
These parameters are compatible with a diabetic state
associated with a partial destruction of pancreatic beta cells,
and the consecutive induction of an inflammatory condition.
Table 1 – Biochemical parameters and TNF-a levels in non-fasting plasma from animals of all experimental groups.
Parameter C M D D-M
Glucose [mg/dL] 165  6 181  9 453  40*,# 309  19*,##,&
Insulin [ng/mL] 1.26  0.17 1.09  0.30 0.45  .06*** 0.37  0.12**,##
Triglycerides [mg/dL] 62  7 54  4 252  25*,# 128  19***,##,&
Fructosamine [mmol/L] 147  26 190  13 239  12** 236  16**
TNF-a [pg/mL] 24.7  1.8 22.4  2.7 123  9.0*,# 96.9  8.6*,#,&&
Results are expressed as the mean  SEM, n = 10.
* Difference from C: P < 0.001.
** Difference from C: P < 0.01.
*** Difference from C: P < 0.05.
# Differences from M: P < 0.001.
## Differences from M: P < 0.05.
& Differences from D: P < 0.001.
&& Differences from D: P < 0.05.
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hyperglycemia (about 2-fold of C) and hypertriglyceridemia
(2-fold of C) associated with diabetes, although the animals
still showed poor metabolic control and inflammatory stress,
as evidenced by the high levels of fructosamine and TNFa (4-
fold of C). In non-diabetic animals, metformin did not affect
any biochemical parameters (M group).
3.2. Diabetes-induced alterations in femoral micro-
architecture are prevented by metformin treatment
To assess the impact of partially insulin-deficient diabetes on
bone microarchitecture, we performed a histomorphometric
analysis of long bones. In femoral metaphysis 2 mm distal from
the cartilage growth plate, 5 mm decalcified bone sections were
stained with H-E to evaluate relative trabecular area and
osteocyte density. In addition, TRAP staining was performed
to evaluate the proportion of osteoclast-covered bone surface in
the primary spongiosa. Metaphyseal bone marrow adiposity
was also evaluated in the stained sections (see Fig. 1). Growth
plate morphometry was evaluated after Alcian Blue staining
(Fig. 1I–L). Analysis of samples from all experimental groups
revealed changes in trabecular bone associated with diabetes
and/or metformin treatment (Table 2). Compared with control
rats, diabetic rats exhibited a slight although not statistically
significant decrease in trabecular area (85%), along with a
significant decrease in osteocyte density (60%) (Fig. 1A–D), TRAP
activity (36%) (Fig. 1E–H) and growth plate height (47%) (Fig. 1I–L).
A significant increase in femoral metaphysis bone marrow
adiposity was detected in diabetic animals (Fig. 1G and K).
Metformin treatment of non-diabetic animals induced a
significant increase in femoral osteocyte density (163% of C)
(Fig. 1B) and TRAP activity (216% of C) (Fig. 1F). In diabetic
animals, metformin treatment partially prevented the diabetes-
induced decrease in osteocyte density (Fig. 1D), TRAP activity
(Fig. 1H) and growth plate height (Fig. 1L), and completely
prevented the increase in bone marrow adiposity (Fig. 1H and L).
3.3. Partially insulin-deficient diabetes impairs the
osteogenic commitment of rat BMPC: effect of in vivo
metformin treatment
We evaluated the effects of a pharmacological induction
of diabetes and the consecutive in vivo treatment withmetformin, on the osteogenic potential of BMPC in vitro. Cells
isolated from animals of each experimental group were
cultured until confluence and then induced to differentiate
in the presence of beta-glycero-phosphate and ascorbic acid
during 15 or 21 days. Type I collagen production and alkaline
phosphatase activity were used as markers of osteoblastic
differentiation. Fig. 1 shows that after 15 days of differentia-
tion, BMPC from D rats exhibited a significant decrease in
collagen production (Fig. 2A) and ALP activity (Fig. 2B). In vivo
treatment with metformin (D-M group) partially or totally
abolished these diabetes-induced alterations in BMPC osteo-
genic capacity. In addition, we confirmed our previous
observation [25] that BMPC from non-diabetic metformin-
treated rats (M) expressed higher levels of ALP than BMPC
from control rats, and showed a significant increase in type I
collagen production. Similarly after 21 days of differentiation,
diabetes decreased the mineralizing capacity of BMPC
cultures (Fig. 2C). In vivo metformin treatment increased
the mineralizing capacity of BMPC from non-diabetic rats (M
group), and completely prevented the diabetes-induced
decrease in mineralization of BMPC from diabetic rats (D-M
group).
3.4. Effect of diabetes and metformin on osteoblastic and
adipogenic transcription factors
We next evaluated possible changes in the expression of the
two major transcription factors involved in osteogenic and
adipogenic differentiation, Runx2 and PPARg. BMPC from
each experimental group were cultured in an osteogenic
media for 15 days and the transcription factors evaluated by
Western immunoblot. Fig. 3A shows that BMPC from D rats
expressed significantly lower levels of Runx2 than C-derived
BMPC. In addition, BMPC from metformin-treated non-
diabetic rats expressed similar levels of Runx2 to control
BMPC, whereas metformin treatment in diabetic rats partially
prevented the diabetes-induced decrease in Runx2 expres-
sion of BMPC.
Analysis of the expression of PPARg showed that this
adipogenic factor was significantly increased in BMPC
obtained from diabetic rats, compared to control BMPC, after
15 days of osteogenic induction (Fig. 3B). In vivo treatment of
diabetic and non-diabetic rats with metformin induced in both
cases a decrease in the expression of PPARg by BMPC.
Fig. 1 – Effect of metformin on diabetes-induced microarchitecture alterations of rat femur. Representative histological
photos of proximal femur from control (A, E, I), metformin-treated non-diabetic (100 mg/kg/day) (B, F, J), untreated diabetic
(C, G, K) and metformin-treated diabetic (D, H, L) rats. After 15 days, all animals were sacrificed, and the femora were
examined by histological procedures. Bone sections were stained with hematoxiline–eosin (A–D), analyzed for TRAP-
activity in the primary spongiosa (E–H) or stained with Alcian Blue (I–L) to assess height of the growth plate. Note the
reduced TRAP-activity (arrow) accompanied by thin growth plate height ($) and high adiposity (arrowhead) in samples
from untreated diabetic versus non-diabetic animals. In contrast, increased TRAP-activity (H), no adiposity (H and L) and a
trend to normalize the growth plate height (L) are observed in the samples of metformin-treated diabetic animals.
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RAGE by BMPC
We next investigated the expression of the receptor RAGE in
BMPC obtained from all experimental groups, prior to and after
15 days of osteogenic differentiation. RAGE was evaluated inTable 2 – Histomorphometric analysis of tissue sections from
Parameter C 
Tb.Ar/T.Ar [%] 39  2 45
N.Ot [#/mm2] 1515  148 2477
TRAP.Ar [%] 6.1  0.7 13.2
Growth plate height [mm] 210  3 226
Tb.Ar/T.Ar, relative trabecular area to tissue area. N.Ot, Osteocyte numb
* Differences from C: P < 0.05.
** Differences from C: P < 0.01.
*** Differences from C: P < 0.001.
# Differences from M: P < 0.05.
## Differences from M: P < 0.001.
& Differences from D: P < 0.05.
&& Differences from D: P < 0.01.
&&& Differences from D: P < 0.001.cell lysates by Western immunoblot. Fig. 4 shows that BMPC
obtained from group C expressed low levels of RAGE. The
expression of RAGE was significantly increased in BMPC from
group D, both prior to and after 15 days of osteogenic
differentiation. In vivo metformin treatment did not modify
RAGE expression in BMPC from non-diabetic animals animals of all experimental groups.
M D D-M
  3 33  2# 41  3
  223*** 898  103*,## 1470  108**,##,&
  2.1*** 2.2  0.5***,## 8.2  0.9*,#,&&&
  8 103  5***,## 128  4***,##,&&
er. TRAP.Ar, relative TRAP area to bone area.
Fig. 2 – In vivo oral administration of metformin in diabetic
and non-diabetic rats reduces the in vitro osteogenic
potential of BMPC. BMPC were isolated from control (C),
metformin-treated non-diabetic (100 mg/kg/day) (M),
untreated diabetic (D) and metformin-treated diabetic (DM)
rats. After confluence, cells were differentiated in an
osteogenic media for 15 days (A,B) or 21 days (C). After
these culture periods, type 1 collagen production (A), ALP
activity (B) and mineralizing capacity (C) were evaluated.
Values are expressed as mean W SEM. Differences from C:
*P < 0.01, **P < 0.001; differences vs. D: #P < 0.001.
Fig. 3 – Induction of Diabetes and oral administration of
metformin alter the expression of Runx2 and PPARg in
BMPC. BMPC were isolated from control (C), metformin-
treated non-diabetic (100 mg/kg/day) (M), untreated
diabetic (D) and metformin-treated diabetic (DM) rats. After
confluence, cells were differentiated in an osteogenic
media for 15 days. Expression of the osteogenic
transcription factor Runx2 and house-keeping protein
actin (A) or adipogenic factor PPARg and actin (B) were
evaluated by Western immunoblot. The blots were
quantified with the Scion beta 2 image program; data were
normalized against actin and expressed as percentage of C
data. Values are expressed as mean W SEM. Differences
from C: *P < 0.05, **P < 0.01, ***P < 0.001; differences from M:
##P < 0.001; differences vs. D: &&P < 0.01, &&&P < 0.001.
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Fig. 4 – Expression of RAGE by BMPC obtained from diabetic
and metformin-treated rats. BMPC were isolated from
control (C), metformin-treated non-diabetic (100 mg/kg/
day) (M), untreated diabetic (D) and metformin-treated
diabetic (DM) rats. After confluence, cells were lysed
directly (A) or after a 15 day differentiation in osteogenic
media (B). In the lysates, expression of RAGE and actin was
evaluated by Western immunoblot and quantified with
the Scion beta 2 image program; RAGE data were
normalized against actin and expressed as percentage of C
data. Values are expressed as the mean W SEM.
Differences from C: **P < 0.01; differences from M:
##P < 0.001; differences vs. D: &&&P < 0.001.
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completely prevented the diabetes-associated up-regulation
of RAGE expression in BMPC.
4. Discussion
Increasing clinical and experimental evidence has accumu-
lated indicating that diabetes mellitus is associated with
metabolic bone disease, osteoporosis and low-impact frac-
tures [32]. Patients with type 1 diabetes tend to have low bone
mineral density and thus an increase in osteoporotic fractures.
Individuals with type 2 diabetes, although characterized by
normal or elevated bone mineral density, also show a
significant increase in fracture risk. The causes of diabetic
bone disease have not been adequately identified, however
type 2 diabetes may arise from two usually concurrent
pathogenic mechanisms, insulin deficiency and insulin resis-
tance, both of which could in theory affect bone metabolism.
One possible approach to circumvent this issue is to evaluate
each mechanism separately by using models of partial insulin
deficiency or of insulin resistance.
Different animal models have been used to investigate the
mechanisms underlying bone alterations in diabetes. Strep-
tozotocin-induced severely insulinopenic rodents have served
as a model for type 1 diabetes. Recently, a model of
streptozotocin-nicotinamide-induced partially insulin-defi-
cient diabetic rats has been described [28]. These animals
are characterized by moderate hyperglycaemia, dislipidemia
and impaired glucose tolerance due to the loss of early-phase
insulin secretion, but not insulin resistance or obesity. Using
this model, in the present study we have investigated the
effect of partially insulin-deficient diabetes with or without
oral metformin treatment, on the microarchitecture of long
bones and on the osteogenic potential of BMPC. Diabetic
animals showed a deficit in insulin secretion (without insulin
resistance), hypertriglyceridemia, elevated serum pro-inflam-
matory cytokine levels, and increased non-enzymatic glyco-
sylation of serum proteins. These observations are in
agreement with previous reports that have used the same
model [33]. Additionally, after two weeks of oral metformin
treatment we found a partial compensation in the biochemical
parameters of diabetic animals.
Since diabetes is clearly associated with metabolic bone
disease, hyperglycaemia has been postulated to be a major
factor that could directly or indirectly affect bone formation
[32]. Hyperglycaemia leads to excessive non-enzymatic
glycosylation of proteins with accumulation of AGEs, thus
increasing AGEs-RAGE interaction as well as the induction of
cytokines (TNF-a, IL-6, HMGB1), oxidative stress and osteo-
clastogenic mediators. In this setting, the normal microarch-
itecture of bone could be affected, leading to a reduction in
bone quality as has been suggested by the results of bone
mechanical loading [9,34]. In addition, diabetes induces lipid
accumulation in the bone marrow, and this could be due to an
excessive adipogenic differentiation of BMPC, thus decreasing
the availability of differentiated osteblasts for bone formation
[22]. The selection of adipogenesis over osteoblastogenesis has
been reported in type 1 diabetes, osteoporosis and disuse
[21,35].
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histomorphometric studies demonstrated a slight decrease in
femoral metaphysis trabecular bone together with an impor-
tant decrease in osteocyte density. We also found a dramatic
increase in the adiposity of the bone marrow of diabetic
animals, an effect that could further contribute to the
deterioration of bone quality. Our present observations are
in agreement with the histomorphometric and micro-com-
puted tomographic analysis of bone performed by other
investigators in NOD and streptozotocin-induced type 1
diabetes mice models [34,36].
Additionally, in our diabetic rats we found a great reduction
in TRAP activity of the primary spongiosa and in the height of
the growth plate. The growth plate height depends on two
antagonistic processes: one in the direction from epiphysis to
metaphysis involving the production, proliferation and hy-
pertrophy of chondrocytes; and another in the opposite
direction representing vascular invasion and cartilage re-
placement by new bone [17]. This last process requires
osteoclastic activity, and so our results of a combined
reduction of TRAP activity in the primary spongiosa and of
growth plate height, are compatible with a decrease in bone
longitudinal growth. Using STZ-induced type 1 diabetic rats,
Silva et al. [34] also found a significant decrease in the growth
plate thickness although they did not evaluate TRAP activity.
On the other hand, other researchers have found a diabetes-
induced increase in osteoclast action, although not in growth
plates and thus associated with an increase in long bone
fragility and a decrease in bone healing [37,38].
The osteocytic network is critical to bone health, since
these cells act as mechanosensors and regulate bone
remodeling [39]. Loss of osteocytes due to apoptosis as a
consequence of diabetes induction has been previously
reported in bone healing and in the cortical tibia of type 1
diabetic rodents [25,40]. It has also been postulated that
apoptotic osteocytes release signals that in turn activate
osteoclasts and bone resorption [41]. One of these signals is the
high mobility group box 1 (HMGB1) protein, which up-
regulates the expression of pro-inflammatory cytokines by
interacting with different receptors, including RAGE for which
it is a physiological ligand. Additionally, induction of diabetes-
associated oxidative stress could be one of the main insults
generating osteocyte apoptosis [42]. These observations
suggest that AGEs-induced ROS production and/or increased
cytokine generation could be responsible for the greatly
diminished osteocyte density observed in our insulin-deficient
diabetic rat model.
Metformin, one the most commonly used oral anti-
hyperglycaemic agents in individuals with type 2 diabetes,
is an insulin sensitizer that has been shown to have
antioxidant effects and to prevent long-term diabetic com-
plications [43]. The use of this drug in patients with type 1
diabetes mellitus is currently being evaluated as an adjunct
therapy to insulin, and as such it has been shown to reduce
insulin requirement, body weight and macrovascular disease,
and to improve endothelial function [44–46]. We have
previously demonstrated that metformin possesses in vitro,
in vivo and ex vivo osteogenic effects [24], although this has
not been adequately studied in diabetic animals. Consequent-
ly, in the present study we investigated the in vivo effect of thisinsulin-sensitizer on bone alterations induced by a diabetic
state that does not show insulin resistance. This fact is
important since any effect of metformin on bone tissue would
probably then be direct, and not due to the bone actions of an
increase in insulin sensitivity. After 2 weeks of oral treatment,
metformin was able to prevent the diabetes-induced trabecu-
lar bone loss and increase in bone marrow adiposity.
Metformin also increased both trabecular osteocytic density
and TRAP activity of the primary spongiosa, in diabetic and
non-diabetic animals. In addition, the decrease in growth
plate height of diabetic animals was partially prevented by
oral treatment with metformin.
BMPC can be induced to differentiate toward different
phenotypes by alterations in their micro-environment. Thus, a
diabetes-induced increase in bone AGEs, cytokines and/or
oxidative stress, could affect the fate of BMPC. To investigate
the mechanisms by which diabetes affects bone formation, we
performed a series of studies with BMPC obtained from the
femora of animals from each experimental group. Our results
demonstrate that the capacity for osteogenic induction of
BMPC from diabetic animals is significantly decreased, as
evaluated by type 1 collagen production, ALP expression and
their capacity for matrix mineralization. These findings in
BMPC of diabetic origin were associated both with a significant
decrease in their expression of the master osteoblastogenic
transcription factor Runx2, and with a significant increase in
their expression of the adipogenic PPARg. All of these
alterations in BMPC osteogenic induction were completely
prevented if the diabetic animals were treated for 2 weeks with
orally administered metformin. The imbalance in Runx2/
PPARg ratio that we are reporting in animals with diabetes is
likely a critical event that could explain the reduced
osteogenic potential of BMPC and in consequence also the
bone histomorphometric alterations that we have observed in
this model. A decrease in Runx2 expression has also been
previously described in STZ-induced type 1 diabetic mice
with marrow ablation [47]. However, other investigators
found no change in the number of osteoblasts, ALP expression
or Runx2 mRNA levels in type 1 diabetic mice [21]. These
authors suggest that diabetic bone loss could be secondary to
an increase in bone marrow adiposity. Our present data,
showing an increase both in the adipogenic factor PPARg and
in the adiposity of the bone marrow, give support to this
hypothesis.
Individuals with long-standing diabetes show an increase
in their systemic accumulation of AGEs, which are then
recognized by specific receptors such as RAGE expressed by
various cell types. Our group and other researchers have
previously demonstrated the expression of RAGE in osteo-
blasts and in BMPC, as well as an AGEs-induced up-regulation
of RAGE in these cell types [11,12,16,48,49]. In vitro, metformin
can prevent the AGEs-induced up-regulation of RAGE in
osteoblasts in culture [17]. To evaluate possible mechanisms
involved in diabetes-induced bone alterations, in the present
study we investigated the expression of RAGE by BMPC
obtained from animals of all groups. In our experimental
conditions, diabetes induced a significant increase in BMPC
RAGE expression, both prior to and after 15 days of osteogenic
induction, and this increase was prevented if the diabetic
animals were treated for 2 weeks with metformin. It has
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 1 ( 2 0 1 3 ) 1 7 7 – 1 8 6 185previously been demonstrated for this streptozotocin-nico-
tinamide diabetic model, that oxidative stress and levels of
inflammatory cytokines are elevated [33]. In coincidence with
those results of other authors, and possibly related to the
diabetes-induced up-regulation of RAGE, we also found an
increase in serum TNFa levels in diabetic animals that was
prevented by oral treatment with metformin.
In conclusion, with our model of partial insulin deficiency
we believe that we have provided sufficient evidence to
adequately confirm the hypothesis of this study, and we are
additionally proposing the modulation of RAGE expression by
BMPC as a possible pathogenic mechanism for diabetic
osteopathy. We consider that the novelty of our study consists
in our ability to have provided a feasible explanation for
alterations in the micro-architecture of diabetic bone: namely,
by a decrease in the osteogenic potential of BMPC. Also by
having demonstrated for the first time in a model of diabetes,
that these alterations of bone tissue can be partially reverted
by oral metformin treatment.
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